The anticancer effect of CpdA was demonstrated via inhibition of both cell growth and the survival of highly malignant prostate cancer cells in a glucocorticoid receptor-dependent fashion (Robertson et al., 2010). The gene discussed is NR3C1; the disease is prostate carcinoma.